Influenza Hemagglutinin (HA) Peptide: Precision Tag for Protein Detection and Purification

Executive Summary: The Influenza Hemagglutinin (HA) Peptide (sequence: YPYDVPDYA) is a nine-amino acid synthetic tag derived from the human influenza hemagglutinin protein, widely adopted for detection, purification, and elution of HA-tagged proteins in molecular biology workflows (APExBIO). It exhibits high solubility (≥55.1 mg/mL in DMSO, ≥100.4 mg/mL in ethanol, ≥46.2 mg/mL in water) and purity (>98%), confirmed by HPLC and mass spectrometry (olaparib.net). The peptide enables efficient, competitive elution of HA fusion proteins from anti-HA antibody-based matrices (Dong et al., 2025). It is central to studies of protein interactions and posttranslational modifications, including ubiquitin-mediated signaling. For optimal performance, storage at -20°C desiccated is recommended, and long-term storage in solution should be avoided (APExBIO).

Biological Rationale

The Influenza Hemagglutinin (HA) Peptide was developed to provide a small, immunogenic tag for fusion protein technology. The nine-residue sequence (YPYDVPDYA) is derived from the HA protein of influenza virus A and is recognized with high affinity by specific monoclonal anti-HA antibodies (olaparib.net). This tag facilitates the detection, quantification, and purification of recombinant proteins expressed in diverse systems, including mammalian, insect, and yeast cells. Its compact size minimizes interference with protein function or localization. The HA peptide tag is a gold standard for studies requiring precise protein quantification, competitive elution, and interaction mapping, such as those investigating ubiquitin-mediated signaling pathways in cancer research (Dong et al., 2025).

Mechanism of Action of Influenza Hemagglutinin (HA) Peptide

When fused to a protein of interest, the HA tag enables selective recognition by anti-HA antibodies. This affinity forms the basis for immunoprecipitation (IP), immunoblotting, and immunofluorescence assays. In competitive elution protocols, excess free HA peptide is used to displace HA-tagged proteins from antibody-bound matrices, enabling native recovery of target proteins without harsh elution conditions. The binding interaction is highly specific, with minimal cross-reactivity to endogenous proteins in eukaryotic cells. The peptide's high solubility ensures effective competition and compatibility with various buffer systems. This mechanism is pivotal in protein-protein interaction studies, notably those dissecting ubiquitination and other posttranslational modification networks, such as the NEDD4L–PRMT5 axis in cancer research (Dong et al., 2025; ay-9944.com).

Evidence & Benchmarks

• High-affinity anti-HA antibodies specifically recognize the YPYDVPDYA epitope, enabling detection and purification of HA-tagged proteins with minimal background (https://doi.org/10.1002/advs.202504704).
• The HA peptide allows for the efficient, competitive elution of HA-tagged fusion proteins from anti-HA matrices, preserving protein activity and structure (https://olaparib.net/index.php?g=Wap&m=Article&a=detail&id=40).
• Solubility of the HA peptide exceeds 55.1 mg/mL in DMSO, 100.4 mg/mL in ethanol, and 46.2 mg/mL in water, ensuring compatibility with diverse experimental workflows (APExBIO).
• Purity of >98% is routinely confirmed by high-performance liquid chromatography (HPLC) and mass spectrometry, supporting reproducible research (APExBIO).
• The HA tag was instrumental in dissecting E3 ligase–substrate interactions, such as the NEDD4L-mediated ubiquitination of PRMT5 in colorectal cancer metastasis models (https://doi.org/10.1002/advs.202504704).

This article extends the mechanistic focus of 'Redefining Translational Research: The Strategic Utility...' by providing detailed benchmarks and outlining workflow integration steps for the Influenza Hemagglutinin (HA) Peptide.

Applications, Limits & Misconceptions

The Influenza Hemagglutinin (HA) Peptide is central to a wide array of molecular biology applications:

• Immunoprecipitation (IP): Enables selective capture and competitive elution of HA-tagged proteins using anti-HA beads or antibodies (epitopeptide.com).
• Protein-Protein Interaction Studies: Essential for mapping transient or stable complexes via co-IP and mass spectrometry (Dong et al., 2025).
• Protein Purification: Allows gentle, buffer-compatible elution of target proteins, preserving functional integrity.
• Detection and Quantification: Facilitates highly specific Western blot, ELISA, and immunofluorescence assays.
• Translational Research: Accelerates analysis of posttranslational modifications, such as ubiquitination in cancer models (perylene-azide.com).

For a broader discussion of specificity and efficiency, see 'Influenza Hemagglutinin (HA) Peptide: Precision Tag for P...', which highlights how this HA tag peptide's solubility and competitive binding characteristics accelerate research; this article adds recent bioanalytical benchmarks and practical limits.

Common Pitfalls or Misconceptions

• Non-Specific Binding: The HA peptide does not bind non-HA antibodies; cross-reactivity is negligible in well-controlled experiments.
• Proteolysis: HA tag does not protect fusion proteins from endogenous protease activity; protease inhibitors are required in lysates.
• Structural Interference: Although small, the HA tag can occasionally affect protein folding or function if positioned near active sites.
• Not a Universal Elution Agent: The HA peptide only works for HA-tagged fusions; it does not competitively elute other epitope tags (e.g., FLAG, Myc).
• Storage Limitation: Long-term stability is reduced in solution; desiccated storage at -20°C is required for optimal shelf life (APExBIO).

Workflow Integration & Parameters

The Influenza Hemagglutinin (HA) Peptide (APExBIO A6004) is supplied as a lyophilized powder at >98% purity. For use, dissolve the peptide in DMSO (≥55.1 mg/mL), ethanol (≥100.4 mg/mL), or water (≥46.2 mg/mL), ensuring full solubilization before addition to immunoprecipitation or elution buffers. Typical competitive elution protocols employ peptide concentrations of 0.5–2 mg/mL at 4°C, with incubation times of 30–60 minutes. The peptide is compatible with a range of anti-HA matrices, including magnetic beads and conventional agarose or sepharose supports. Avoid repeated freeze-thaw cycles and prepare aliquots for single-use to maintain integrity. For optimal results, use freshly prepared solutions and store the lyophilized product desiccated at -20°C. The peptide’s performance has been validated in workflows studying E3 ligase–substrate interactions, notably the NEDD4L–PRMT5 axis in colorectal cancer liver metastasis (Dong et al., 2025).

For a comprehensive comparison of epitope tags and workflow optimization strategies, see 'Influenza Hemagglutinin (HA) Peptide: Precision Epitope T...'; this article provides updated solubility and purity benchmarks and detailed integration guidance for APExBIO’s HA peptide.

Conclusion & Outlook

The Influenza Hemagglutinin (HA) Peptide is a validated, high-performance tag for protein detection, purification, and interaction mapping in modern molecular biology. Its specificity, solubility, and compatibility with competitive elution protocols have made it indispensable for rigorous immunoprecipitation and interaction studies, including those dissecting complex signaling pathways like ubiquitin-mediated modification and cancer metastasis. As workflows evolve to require higher throughput and mechanistic resolution, high-purity HA tag peptides from APExBIO will remain central to translational research and clinical proteomics. Future innovations may include multiplexed epitope tagging and integration with automated, quantitative platforms.